Research Article

Global Stability of Delayed Viral Infection Models with Nonlinear Antibody and CTL Immune Responses and General Incidence Rate

Hui Miao, Zhidong Teng, and Zhiming Li

College of Mathematics and System Sciences, Xinjiang University, Xinjiang, Urumqi 830046, China

Correspondence should be addressed to Zhidong Teng; zhidong_teng@sina.com

Received 12 August 2016; Accepted 22 November 2016

Academic Editor: Fabien Crauste

Copyright © 2016 Hui Miao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The dynamical behaviors for a five-dimensional viral infection model with three delays which describes the interactions of antibody, cytotoxic T-lymphocyte (CTL) immune responses, and nonlinear incidence rate are investigated. The threshold values for viral infection, antibody response, CTL immune response, CTL immune competition, and antibody competition, respectively, are established. Under certain assumptions, the threshold value conditions on the global stability of the infection-free, immune-free, antibody response, CTL immune response, and interior equilibria are proved by using the Lyapunov functionals method, respectively. Immune delay as a bifurcation parameter is further investigated. The numerical simulations are performed in order to illustrate the dynamical behavior of the model.

1. Introduction

In recent years, many authors have formulated and studied mathematical models which describe the dynamics of virus population in vivo. These provide insights in our understanding of HIV (human immunodeficiency virus) and other viruses, such as HBV (hepatitis B virus) and HCV (hepatitis C virus) [1–34]. In particular, the global stability of steady states for these models will give us a detailed information and enhance our understanding about the viral dynamics.

During viral infections, the immune system reacts against virus. The antibody and CTL play the crucial roles in preventing and modulating infections. The antibody response is implemented by the functioning of immunocompetent B lymphocytes. The CTL immune response has the ability to suppress the virus replication in vivo. Hence, in order to prevent virus infection, an effective vaccine needs both strong neutralizing antibody and CTL immune responses [1, 2, 14, 18–23, 25–32]. Based on these, it is of interest for us to investigate whether sustained oscillations are the result of delayed viral infection model. This provides us with the motivation to conduct our work. In [2], Balasubramaniam et al. developed the viral infection model by incorporating immune delays and Beddington-DeAngelis incidence rate

\[
\begin{align*}
\frac{dx(t)}{dt} &= \lambda - dx(t) - \frac{\beta \left(1 - e_{rt}\right) x(t) v(t)}{1 + mx(t) + nv(t)}, \\
\frac{dy(t)}{dt} &= \frac{\beta \left(1 - e_{rt}\right) x(t) v(t)}{1 + mx(t) + nv(t)} - ay(t) - py(t) z(t), \\
\frac{dv(t)}{dt} &= \frac{k \left(1 - e_{pi}\right) y(t) - uv(t) - qv(t) w(t)}, \\
\frac{dw(t)}{dt} &= g v(t) w(t) - hw(t), \\
\frac{dz(t)}{dt} &= cy(t - \tau) z(t - \tau) - bz(t),
\end{align*}
\]

(1)

where \( x, y, v, w, \) and \( z \) denote the concentrations of susceptible host cells, infected cells, free virus, antibody responses, and CTL immune responses, respectively. The local and global stability of the infection-free equilibrium and infected equilibrium and the existence of Hopf bifurcation are
obtained. Furthermore, by using the Nyquist criterion, the estimation of the length of the delay to preserve stability of the infected equilibrium is obtained.

Motivated by the work in [1, 2, 20, 21], in the present paper we propose a general viral infection model with three time delays which describes the interactions of antibody, CTL immune responses, and nonlinear incidence rate

\[
\frac{dx(t)}{dt} = s(x) - f(x, v),
\]

\[
\frac{dy(t)}{dt} = e^{-m_1 \tau_1} f(x(t - \tau_1), v(t - \tau_1)) - a_1(y)
\]

\[- p g_1(y) g_4(z),
\]

\[
\frac{dv(t)}{dt} = ke^{-m_2 \tau_2} g_1(y(t - \tau_2)) - ug_2(v)
\]

\[- q g_2(v) g_3(w),
\]

\[
\frac{dz(t)}{dt} =cg_1(y(t - \tau_3)) g_4(z(t - \tau_3)) - bg_4(z),
\]

\[
\frac{dw(t)}{dt} = rg_2(v) g_3(w) - h g_3(w),
\]

where \(s(x)\) denotes the intrinsic growth rate of uninfected target cells accounting for both production and natural mortality. In the literature of virus dynamics, the typical forms of the growth rate are \(s(x) = \lambda - dx\) and \(s(x) = \lambda - dx + rx(1- x/K)\), where \(\lambda, d, r, K\) are positive real numbers [4, 13, 15, 16, 18, 20–23, 26–32, 34].

We assume that the incidence of new infections of target cells occurs at a rate \(f(x, v)\). This form of incident rate is general to encompass several forms such as bilinear incidence \(\beta x v[4, 13]\), saturated incidence \(\beta x v/(1 + bv)[16]\), Holling type II functional response \(\beta x v/(1 + ax)[15]\), and Crowley–Martin incidence \(\beta x v/(1 + ax + bx + abxv)[12, 35]\), where \(\beta, a, b\) are positive constants.

It is also assumed that the death rates of the infected target cells, viruses, antibody, and CTLs depend on their concentrations. These rates are given by \(a g_1(y)\), \(u g_2(v)\), \(h g_3(w)\), and \(b g_4(z)\), respectively. The neutralization rate of viruses and the activation rate of B cells are proportional to the product of the removal rates of the viruses and B cells. Let \(p g_1(y) g_3(w)\) and \(r g_2(v) g_3(w)\) be the neutralization rate of viruses and activation rate of B cells, respectively. The typical forms can be seen as \(q w v\) and \(r w v\) [1, 2, 20, 21, 31, 32]. Accordingly, let \(p g_1(y) g_3(z)\) and \(c g_1(y) g_4(z)\) be the killing rate of infected cells and the birth rate of the CTL cells, respectively. The typical forms are \(p y z\) and \(c y z\) that appear in several papers [1, 2, 14, 20, 22, 27, 30, 34].

For model (2), based on the epidemiological background, we assume that virus production occurs after the virus entry by the time delay \(\tau_1\). The probability of surviving the time period from \(t - \tau_1\) to \(t\) is \(e^{-m_1 \tau_1}\). Let \(\tau_2\) be the maturation time of the newly produced viruses. The constant \(e^{-m_2 \tau_2}\) denotes the surviving rate of virus during the period delay. Antigenic stimulation generating CTL cell may need a period of time \(\tau_3\).

In this paper, our purpose is to investigate the dynamical properties of model (2), including the local and global stability of equilibria. The reproduction numbers for viral infection, antibody response, CTL immune response, CTL immune competition, and antibody response, respectively, are calculated. By using Lyapunov functional methods and LaSalle’s invariance principle, the threshold conditions for the global asymptotic stability of infection-free equilibrium \(E_0\), immune-free equilibrium \(E_1\), infection equilibrium \(E_2\) only with antibody response, and infection equilibrium \(E_3\) only with CTL immune response and infection equilibrium \(E_4\) with both antibody and CTL immune responses when the delay \(\tau_3 = 0\), respectively, are established. By using the linearization method, the instability of equilibria \(E_0, E_1, E_2,\) and \(E_3\), respectively, is also established. Furthermore, by using the numerical simulation method, we will discuss the existence of the Hopf bifurcation and stability switches at equilibria \(E_1\) and \(E_4\) when \(\tau_3 > 0\).

The organization of this paper is as follows. In the next section, the basic properties of model (2) for the positivity and boundedness of solutions, the threshold values, and the existence of equilibria are discussed. In Section 3, the threshold conditions on the global stability and instability of equilibria \(E_0, E_1,\) and \(E_2\) are proved. When \(\tau_3 = 0\), the threshold conditions on the global stability and instability for equilibria \(E_3\) and \(E_4\) are stated and proved. In Section 4, the numerical simulations are given to further discuss the stability of equilibria \(E_1\) and \(E_2\) when \(\tau_3 > 0\). It is shown that the Hopf bifurcation and stability switches at these equilibria occur as \(\tau_3\) increases. In the last section, we offer a brief conclusion.

## 2. Preliminaries

Let \(\tau = \max\{\tau_1, \tau_2, \tau_3\}\) and \(R^5\) = \{(\(x_i, x_2, x_3, x_4, x_5\)): \(x_i \geq 0, i = 1, 2, \ldots, 5\)\}. \(C[\tau, 0], R^5\) denotes the space of continuous functions mapping interval \([\tau, 0]\) into \(R^5\) with norm \(\|\phi\| = \sup_{t \in [\tau, 0]} |\phi(t)|\) for any \(\phi \in C[\tau, 0], R^5\).

The initial conditions for any solutions of model (2) are given as follows:

\[
(x(\theta), y(\theta), v(\theta), z(\theta), w(\theta))
\]

\[= (\phi_1(\theta), \phi_2(\theta), \phi_3(\theta), \phi_4(\theta), \phi_5(\theta)), \quad (3)
\]

\[\phi_i(\theta) \geq 0, \quad \theta \in [\tau, 0], \quad i = 1, 2, 3, 4, 5,
\]

where \((\phi_1, \phi_2, \phi_3, \phi_4, \phi_5) \in C[\tau, 0], R^5\). By the fundamental theory of functional differential equation [36], model (2) admits a unique solution \((x(t), y(t), v(t), z(t), w(t))\) satisfying initial conditions (3).

In this paper, we firstly introduce the following assumptions:

\[(H_1) s(x)\) is continuously differentiable. There exists \(\exists > 0\) such that \(s(\bar{x}) = 0\) and \(s'(\bar{x}) < 0\).

\[(H_2) f(x, v)\) is continuously differentiable; \(f(x, v) > 0\) for \(x \in (0, \infty), v \in (0, \infty); f(x, v) = 0\) if and only if \(x = 0\) or \(v = 0; \partial f(x, v)/\partial x \geq 0\) and \(\partial f(x, v)/\partial v \geq 0\) for all \(x \geq 0\) and \(v \geq 0; (d/dx)(\partial f(x, v)/\partial v) \geq 0\) for all \(x \geq 0\).
\((H_3)\) \(g_i(\xi) (i = 1, 2, 3, 4)\) is strictly increasing on \([0, \infty)\); 
\(\lim_{x \to \infty} g_i(\xi) = +\infty\); and there exists \(k_i > 0\) such that 
\(g_i(\xi) \geq k_i \xi\) for any \(\xi \geq 0\); \(g(0) = 0\) and \(g_1'(0) = 1\).

\((H_4)\) \(f(x, v)/g_2(v)\) is nonincreasing with respect to \(v\) for \(v \in (0, \infty)\).

From \((H_1)\) we easily obtain that \(s(x) > 0\) for all \(0 < x < \bar{x}\) and \(s(x) < 0\) for all \(x > \bar{x}\). Assumption \((H_1)\) shows that the number of healthy cells \(x\) has a maximum capacity \(\bar{x}\) in the absence of infection. When \(x < \bar{x}\), \(s(x)\) has a positive growth; if \(x > \bar{x}\) it has a negative growth. Assumption \((H_2)\) implies that there are no new infected cells (i.e., \(f(x, v) = 0\)) without healthy cells \((x = 0)\) or virus \((v = 0)\). The higher the number of healthy cells \(x\) is, the higher the number of healthy cells \(x\) which are infected in the unit time will be. Similarly, the higher the amount of virus \(v\) is, the higher the number of healthy cells \(x\) which are infected in the unit time will be. Assumption \((H_3)\) assumes that the death rates of the infected target cells \(y\), virus \(v\), antibodies \(w\), and CTLs \(z\) depend on their concentrations. If these numbers \(y, v, w, z\) increase, the corresponding rates \(a_g(y), u_g(v), h_g(w), b_g(z)\) will increase, and the ratio \(g_i(\xi)/\xi\) is no less than a positive constant for \(i = 1, 2, 3, 4\). Finally, assumption \((H_2)\) indicates that both the rate of new infections of target cells and the virus clearance rate increase according to the level of virus. However, the corresponding ratio is nonincreasing.

Using an argument similar to [14] we have the following result.

**Theorem 1.** Assume that \((H_1)-(H_4)\) hold. Let \((x(t), y(t), v(t), z(t), w(t))\) be the solution of model \((2)\) with initial conditions \((3)\); then \((x(t), y(t), v(t), z(t), w(t))\) is positive and ultimately bounded.

Next, we discuss the existence and uniqueness of equilibria of model \((2)\). We know that any equilibrium \(E = (x, y, v, z, w)\) of model \((2)\) satisfies

\[
\begin{align*}
    s(x) - f(x, v) &= 0, \\
    e^{-m_1} f(x, v) - a g_1(y) - p g_1(y) g_4(z) &= 0, \\
    k e^{-m_2} g_1(y) - u g_2(v) - q g_2(v) g_3(w) &= 0, \\
    c g_1(y) g_4(z) - b g_4(z) &= 0, \\
    r g_2(v) g_3(w) - h g_3(w) &= 0.
\end{align*}
\]

It is clear from \((4)\) that model \((2)\) has a unique infection-free equilibrium \(E_0 = (\bar{x}, 0, 0, 0, 0)\). When \(y = 0\), from \((4)\) we have \(s(x) = f(x, v) + g_2(v)(u + g_4(z)) = 0\), \(g_4(z) = 0\), and \(r g_2(v) g_3(w) - h g_3(w) = 0\). Solving these equations, we have \(x = \bar{x}, v = 0, z = 0, w = 0\). When \(v = 0\), from \((4)\) we have \(s(x) = 0, g_1(y) g_4(z) = 0\), \(g_1(y) = 0, g_4(z) = 0\), and \(r g_2(v) g_3(w) - h g_3(w) = 0\). Solving these equations, we have \(x = \bar{x}, v = 0, z = 0, w = 0\). Therefore, besides equilibrium \(E_0\), model \((2)\) only has the following four possible equilibria: \(E_1 = (x_1, y_1, v_1, 0, 0), E_2 = (x_2, y_2, v_2, 0, w_2), E_3 = (x_3, y_3, v_3, z_3, 0),\) and \(E_4 = (x_4, y_4, v_4, z_4, w_4)\).

The existence of immune-free equilibrium \(E_1 = (x_1, y_1, v_1, 0, 0)\) is equivalent to the existence of positive solution \((x_1, y_1, v_1)\) of the following equations:

\[
    s(x) = f(x, v) = au e^{m_1} g_1(y) = \frac{au e^{m_1} g_1(y)}{k} g_2(v). \tag{5}
\]

By \((H_3)\), the inverse function \(g_2^{-1}(v)\) exists. Solving \(s(x) = (au e^{m_1} g_1(y) / k) g_2(v)\), we have \(v = g_2^{-1}(ks(x)) / au e^{m_1} g_1(y) / k\) with \(\varphi(\overline{x}) = 0\) and \(\varphi(0) = v_0\), where \(v_0\) is the unique positive root of equation \(s(0) = (au e^{m_1} g_1(y) / k) g_2(v)\). Define \(G(x) = f(x, g_2(v)(x)) - (au e^{m_1} g_1(y) / k) g_2(v)\). Then \(G(0) = -(au e^{m_1} g_1(y) / k) g_2(v_0) < 0\) and \(G(\overline{x}) = 0\).

Define the basic reproduction number for viral infection

\[
    R_0 = \frac{ke^{-m_1} g_1(y)}{au} \frac{\partial f(\overline{x}, 0)}{\partial v}. \tag{6}
\]

Note that

\[
\begin{align*}
    G'(\overline{x}) &= \frac{\partial f(\overline{x}, 0)}{\partial x} x + \frac{\partial f(\overline{x}, 0)}{\partial v} v \phi'(\overline{x}) \\
    &= \frac{-a u e^{m_1} g_1(y)}{k} \frac{g_2'(0)}{g_2(0)} \phi'(\overline{x}) \\
    &= \frac{a u e^{m_1} g_1(y)}{k} \phi'(\overline{x}) \left( \frac{k}{a u e^{m_1} g_1(y)} \frac{\partial f(\overline{x}, 0)}{\partial v} - 1 \right) \\
    &= s'(\overline{x}) (R_0 - 1).
\end{align*}
\]

Thus, if \(R_0 > 1\), then \(G'(\overline{x}) < 0\). This implies that there exists \(x_1 \in (0, \overline{x})\) such that \(G(x_1) = 0\). The value of \(v_1\) is given by \(v_1 = g_2^{-1}(ks(x_1))\). \((H_2)\) ensures that \(ke^{-m_1} g_1(y) = u g_2(v_1)\) has a unique positive solution \(y_1 = g_1^{-1}(ue^{m_1} g_1(y)/g_2(v_1))\). Therefore, \(E_1\) exists if \(R_0 > 1\).

Next we show that \(E_2 = (x_2, y_2, v_2, 0, w_2)\) is a unique immune-free equilibrium. Otherwise, there exists another \(E_2^* = (x_2^*, y_2^*, v_2^*, 0, 0)\). Without loss of generality, we assume that \(x_2^* < x_2\), and then \((s(x_2^*) > s(x_1))\). Meanwhile, \(ks(x_2^*) = au e^{m_1} g_1(y) = u g_2(v_1)\) (By \((H_3)\) and \((H_4)\), we have \(v_2^* > v_2\)). Since \(x_2^* < x_1\), we obtain \((f(x_2^*, v_2^*), g(x_2^*, v_2^*)) < (f(x_1, v_2), g(x_1, v_2))\). Thus, \(E_1\) is a unique equilibrium.

We consider the existence of infection equilibrium \(E_2 = (x_2, y_2, v_2, 0, w_2)\) with only antibody response. It is clear that \(v_2 = g_2^{-1}(h/vr)\). Define \(F(x) = s(x) - f(x, v_2)\). By \((H_1)\) and \((H_2)\), we obtain \(F(x) < 0\). Since \(F(0) = s(0) > 0\) and \(F(\overline{x}) = s(\overline{x}) - f(\overline{x}, v_2) < 0\), there exists a unique \(x_2 \in (0, \overline{x})\) such that \(F(x_2) = 0\). Then, we have \(y_2 = g_1^{-1}(e^{-m_1} f(x_2, y_2)/a)\).

Define the constant

\[
    R_1 = \frac{ke^{-m_1} g_1(y)}{u} \frac{f(x_2, y_2)}{g_2(v_2)}. \tag{8}
\]
which is called the antibody response reproductive number of model (2). Solving $w_2$ from (4), we obtain that

$$w_2 = g_3^{-1} \left( \frac{ke^{-m_1 z_1} g_1(y_3) - u g_2(v_2)}{q g_2(v_2)} \right)$$

$$= g_3^{-1} \left( \frac{u (R_1 - 1)}{q} \right) > 0 \text{ if } R_1 > 1.$$

Therefore, $E_2$ exists and is unique if $R_1 > 1$.

We consider the existence of infection equilibrium $E_3 = (x_3, y_3, v_3, z_3, 0)$ with only CTL immune response. From the third and fourth equations of (4), we obtain unique $y_3 = g_3^{-1}(b/c)$ and $v_3 = g_2^{-1}(bke^{-m_1 z_1}/au)$. Define $F(x) = s(x) - f(x, v_3)$. By $(H_1)$ and $(H_2)$, we obtain $F'(x) < 0$. Since $F(0) = s(0) > 0$ and $F(\infty) = s(\infty) - f(\infty, v_3) < 0$, there exists a unique $x_3 \in (0, \infty)$ such that $F(x_3) = 0$.

Define the constant

$$R_2 = \frac{ke^{-m_1 z_1 - m_2 z_2}}{au} f(x_3, v_3) g_2(v_3),$$

which is called the CTL immune response reproductive number of model (2). Solving the second equation for $z$ yields

$$z_3 = g_4^{-1} \left( \frac{e^{-m_1 z_1} f(x_3, v_3) - a g_1(y_3)}{pg_1(y_3)} \right)$$

$$= g_4^{-1} \left( \frac{a (R_2 - 1)}{p} \right) > 0 \text{ if } R_2 > 1.$$

Therefore, $E_3$ exists and is unique if $R_2 > 1$.

Lastly, we consider the existence of infection equilibrium $E_4 = (x_4, y_4, v_4, z_4, w_4)$ with both antibody and CTL immune responses. From the fourth and fifth equation of (4), we obtain unique $y_4 = g_3^{-1}(b/c)$ and $v_4 = g_2^{-1}(bke^{-m_1 z_1}/au)$. Define $F(x) = s(x) - f(x, v_3)$. By $(H_1)$ and $(H_2)$, we obtain $F'(x) < 0$. Since $F(0) = s(0) > 0$ and $F(\infty) = s(\infty) - f(\infty, v_3) < 0$, there exists a unique $x_4 \in (0, \infty)$ such that $F(x_4) = 0$.

Define the constants

$$R_3 = \frac{c f(x_4, v_4)}{ab e^{m_1 z_1}},$$

$$R_4 = \frac{kbr}{uch e^{m_1 z_1}},$$

which are called the CTL immune response competitive reproductive number and the antibody response competitive reproductive number of model (2), respectively. Solving the second equation for $z$ yields a unique

$$z_4 = g_4^{-1} \left( \frac{e^{-m_1 z_1} f(x_4, v_4) - a g_1(y_4)}{pg_1(y_4)} \right)$$

$$= g_4^{-1} \left( \frac{a (R_3 - 1)}{p} \right) > 0 \text{ if } R_3 > 1.$$

Solving the third equation for $w$, we further obtain a unique

$$w_4 = g_3^{-1} \left( \frac{ke^{-m_1 z_1} g_1(y_4) - u g_2(v_4)}{q g_2(v_4)} \right)$$

$$= g_3^{-1} \left( \frac{u (R_4 - 1)}{q} \right) > 0 \text{ if } R_4 > 1.$$

Therefore, $E_4$ exists and is unique if $R_3 > 1$ and $R_4 > 1$.

Remark 2. From $(H_3)$ and $(H_4)$, we obtain $R_1 < R_0$ and $R_2 < R_0$. In fact,

$$R_1 = \frac{ke^{-m_1 z_1 - m_2 z_2}}{u} f(x_2, v_2) g_2(v_2)$$

$$\leq \frac{ke^{-m_1 z_1 - m_2 z_2}}{u} \lim_{v \to 0^+} f(x_2, v) g_2(v)$$

$$= \frac{ke^{-m_1 z_1 - m_2 z_2}}{u g_2(0)} \frac{\partial f(x_2, 0)}{\partial v} < \frac{ke^{-m_1 z_1 - m_2 z_2}}{ug_2(0)} \frac{\partial f(\infty, 0)}{\partial v}$$

$$= R_0,$$

$$R_3 \geq \frac{ke^{-m_1 z_1 - m_2 z_2}}{ug_2(0)} \frac{\partial f(x_2, 0)}{\partial v} < \frac{ke^{-m_1 z_1 - m_2 z_2}}{ug_2(0)} \frac{\partial f(\infty, 0)}{\partial v}$$

$$= R_0.$$

3. Stability Analysis

3.1. Stability of Equilibrium $E_0$

Theorem 3. (a) If $R_0 \leq 1$, then infection-free equilibrium $E_0$ is globally asymptotically stable.

(b) If $R_0 > 1$, then $E_0$ is unstable.

Proof. Consider conclusion (a). Define a Lyapunov functional $V_1(t)$ as follows:

$$V_1(t) = x(t) - \int_0^{\infty} f(\theta, v) \ d\theta + m_1 y(t)$$

$$+ \frac{ae^{m_1 z_1}}{k} \nu(t) + \frac{pe^{m_1 z_1}}{c} z(t)$$

$$+ \int_{t - \tau_1}^0 f(x(t + s), v(t + s)) \ ds$$

$$+ \frac{ae^{m_1 z_1}}{c} \int_{t - \tau_2}^0 g_1(y(t + s)) \ ds$$

Computational and Mathematical Methods in Medicine
Calculating the time derivative of $V_1(t)$ along solutions of model (2), we obtain

$$
\frac{dV_1(t)}{dt} = s(x) \left( 1 - \lim_{v \to 0} \frac{f(\bar{x}, v)}{f(x, v)} \right) + f(x, v)
$$

(16)

It follows that

$$
\frac{dV_1(t)}{dt} \leq \frac{\alpha u e^{m_1 \tau_1 + m_2 \tau_2}}{k} g_2(v)(R_0 - 1). \quad (19)
$$

Note that $\lim_{v \to 0} f(\bar{x}, v) / f(x, v) = 1$, and

$$
\lim_{v \to 0} \frac{f(\bar{x}, v)}{g_2(v)} \leq \lim_{v \to 0} \frac{f(x, v)}{g_2(v)} \frac{\partial f(\bar{x}, 0)}{\partial v} / \partial v
$$

(18)

Next, we consider conclusion (b). By computing, the characteristic equation of the linearization system of model (2) at $E_0$ is

$$
(\lambda + h g_3(0))(\lambda + b g'_4(0))(\lambda - s'(\bar{x})) f'(\lambda) = 0, \quad (20)
$$

where

$$
f'(\lambda) = \lambda^2 + (a + u) \lambda + au - k \frac{\partial f(\bar{x}, 0)}{\partial v} e^{-(m_1 \lambda) \tau_1} e^{-(m_2 \lambda) \tau_2} e^{-(m_3 \lambda) \tau_3}. \quad (21)
$$

When $R_0 > 1$, we have $f(0) = au - k(\partial f(\bar{x}, 0)) / \partial v) e^{-(m_1 \lambda) \tau_1} e^{-(m_2 \lambda) \tau_2} < 0$ and $\lim_{\lambda \to \infty} f(\lambda) = +\infty$. Hence, there is $\lambda > 0$ such that $f(\lambda) = 0$. Therefore, when $R_0 > 1$, $E_0$ is unstable. This completes the proof.

Remark 4. Theorem 3 shows that if only equilibrium $E_0$ exists, then it is globally asymptotically stable, and delays $\tau_1$, $\tau_2$, and $\tau_3$ do not impact the stability of $E_0$.

3.2. Stability of Equilibrium $E_1$. Firstly, we introduce two lemmas which will be used in the proof of Theorem 7.

Lemma 5. Suppose that (H1)–(H4) hold and $R_0 > 1$. Let $x_2$ and $y_2$ satisfy $\theta_2(y_2) = h/r$ and $s(x_2) = f(x_2, y_2)$. Then for equilibrium $E_1 = (x_1, y_1, v_1, 0, 0)$, sign$(x_2 - x_1) = sign(v_1 - v_2) = sign(R_1 - 1)$.

Proof. Since $s(x_1) = f(x_1, v_1)$, we have

$$
s(x_2) - s(x_1) = (f(x_2, v_2) - f(x_1, v_1)) + (f(x_1, v_2) - f(x_1, v_1)). \quad (22)
$$

By (H1) and (H2), we get $sign(x_2 - x_1) = sign(v_1 - v_2)$. Using $(ke^{-m_1 \tau_1 - m_2 \tau_2} / au) f(x_1, v_1) / g_2(v_1)) = 1$, we have

$$
R_1 - 1 = \frac{k}{\alpha u e^{m_1 \tau_1 + m_2 \tau_2}} \left( \frac{f(x_2, v_2) - f(x_1, v_1)}{g_2(v_2) - g_2(v_1)} \right). \quad (23)
$$

By (H4), it follows that $sign(R_1 - 1) = sign(v_1 - v_2)$.

Lemma 6. Suppose that (H1)–(H4) hold and $R_0 > 1$. Let $x_3$, $y_3$, and $v_3$ satisfy $\theta_2(v_3) = k b e^{m_1 \tau_1 / uc} g_1(y_3) = b/c$, and $s(x_3) = f(x_3, y_3)$. Then, for equilibrium $E_1 = (x_1, y_1, v_1, 0, 0)$, sign$(x_3 - x_1) = sign(v_1 - v_3) = sign(y_1 - y_3) = sign(R_2 - 1)$.

Proof. Since $g_1(y_3) = (ue^{m_2 \tau_2} / k) g_2(v_3)$ and $g_1(y_3) = (ue^{m_2 \tau_2} / k) g_2(v_3)$, we have $sign(v_1 - v_3) = sign(y_1 - y_3)$. Since $s(x_3) = f(x_1, v_1)$, one has

$$
s(x_3) - s(x_1) = (f(x_2, v_2) - f(x_1, v_1)) + (f(x_1, v_2) - f(x_1, v_1)). \quad (24)
$$

By (H1) and (H2), we get $sign(x_3 - x_1) = sign(v_1 - v_3)$, and

$$
R_2 - 1 = \frac{k}{\alpha u e^{m_1 \tau_1 + m_2 \tau_2}} \left( \frac{f(x_3, v_3)}{g_2(v_3)} - \frac{f(x_3, v_1)}{g_2(v_1)} \right). \quad (25)
$$

By (H2) and (H4), we further have $sign(R_2 - 1) = sign(x_3 - x_1)$.

This completes the proof.

Theorem 7. Let $R_0 > 1$. (a) If $R_1 \leq 1$ and $R_2 \leq 1$, then immune-free equilibrium $E_1$ is globally asymptotically stable. (b) If $R_1 > 1$ or $R_2 > 1$, then $E_1$ is unstable.
Proof. Consider conclusion (a). Denote $H(\xi) = \xi - 1 - \ln \xi$ with $\xi \in R_+$. Define a Lyapunov functional $V_2(t)$ as follows:

$$V_2(t) = x(t) - \int_{t_1}^{x(t)} \frac{f(x_1, v_1)}{f(\theta, v_1)} d\theta$$

$$+ \frac{ae^{m_1 \tau_1}}{k} \left( y(t) - \int_{t_1}^{y(t)} \frac{g_1(y_1)}{g_1(\theta)} d\theta \right)$$

$$+ \frac{pe^{m_1 \tau_1}}{c} \left( v(t) - \int_{t_1}^{v(t)} \frac{g_2(v_1)}{g_2(\theta)} d\theta \right)$$

$$+ \frac{pe^{m_1 \tau_1}}{c} \left( w(t) - \int_{t_1}^{w(t)} \frac{h_2(w_1)}{h_2(\theta)} d\theta \right)$$

Calculating the derivative of $V_2(t)$ along solutions of model (2), we obtain

$$\frac{dV_2(t)}{dt} = s(x) \left( 1 - \frac{f(x_1, v_1)}{f(x, v_1)} \right)$$

$$+ f(x, v) \frac{f(x_1, v_1)}{f(x, v_1)} - \frac{ae^{m_1 \tau_1 + m_2 \tau_2}}{k} g_2(v)$$

$$+ M_1 + M_2,$$

where

$$M_1 = \frac{pe^{m_1 \tau_1}}{c} g_1(y_1) g_4(z)$$

$$+ \frac{ae^{m_1 \tau_1 + m_2 \tau_2}}{k} g_2(v_1) g_3(w)$$

$$\cdot \frac{g_3(w) = pe^{m_1 \tau_1} g_4(z) (g_1(y_1) - g_1(y_3))}{k}$$

$$+ \frac{ae^{m_1 \tau_1 + m_2 \tau_2}}{k} g_3(w) (g_2(v_1) - g_2(v_2)),$$

$$M_2 = f(x_1, v_1) \left( 2 \right)$$

$$- \frac{g_1(y_1) f(x(t-\tau_1), v(t-\tau_1))}{g_1(y) f(x_1, v_1)}$$

$$- \frac{g_2(v_1) g_2(y(t-\tau_2))}{g_2(v_1) g_2(v)}$$

Therefore,

$$\frac{dV_2(t)}{dt} = s(x) - s(x_1) \left( 1 - \frac{f(x_1, v_1)}{f(x, v_1)} \right)$$

$$+ f(x, v) \frac{f(x_1, v_1)}{f(x, v_1)} - M_1 + M_2,$$

Note that $s(x) - s(x_1)(1 - f(x_1, v_1)/f(x, v_1)) \leq 0$, and

$$\left( \frac{f(x, v)}{f(x_1, v_1)} - 1 \right) \left( \frac{g_2(v_1)}{g_2(v)} - \frac{f(x_1, v_1)}{f(x, v_1)} \right) \leq 0$$

for $t \geq 0$.

Lemmas 5 and 6 imply that $y_1 \leq y_3$ and $v_1 \leq v_2$ if $R_1 \leq 1$ and $R_2 \leq 1$. It then follows from the monotonicity of $g_1$ and $g_2$ that $M_1 \leq 0$. We have $dV_2(t)/dt \leq 0$, and $dV_2(t)/dt = 0$ if and only if $x(t) = x_1, y(t) = y_1, v(t) = v_1, z(t) = 0$, and $w(t) = 0$. From LaSalle's invariance principle [36], we finally have that equilibrium $E_1$ of model (2) is globally asymptotically stable when $R_0 > 1$, $R_1 \leq 1$, and $R_2 \leq 1$.

Next, consider conclusion (b). By computing, the characteristic equation of the linearization system of model (2) at $E_1$ is

$$(\lambda + h - rg_2(v_1)) f_1(\lambda) f_2(\lambda) = 0,$$

where $f_1(\lambda) = \lambda + b - cg_1(y_1)e^{-\lambda \tau_2}$ and
Lemma. Since \( \exists \) exist, then such that

\[
\lim_{\lambda \to +\infty} V(\lambda) = 0.
\]

3.3 Stability of Equilibrium \( E_2 \). We firstly have the following Lemma.

Lemma 9. Suppose \( R_1 > 1 \) and \( R_3 \leq 1 \). Let \( \overline{x}_4 = (x_4, y_4, \overline{w}_4, \overline{z}_4) \) be the solution of equation (4) with \( \overline{v}_4 = g_2^{-1}(h/r) \) and \( \overline{y}_4 = g_1^{-1}(b/c) \). Then for equilibrium \( E_2 = (x_2, y_2, v_2, 0, w_2, z_2) \), we get

\[
e^{-m_1 \tau_1} f(x_2, v_2) = a g_1(y_2),
\]

\[
e^{-m_1 \tau_1} f(\overline{x}_4, \overline{v}_4) = a g_1(\overline{y}_4) + p g_1(\overline{y}_4) g_4(\overline{z}_4),
\]

it follows that \( y_2 \leq \overline{y}_4 \) if \( R_1 > 1 \) and \( R_3 \leq 1 \). This completes the proof.

Remark 8. Theorem 7 shows that if only equilibria \( E_0 \) and \( E_1 \) exist, then \( E_1 \) is globally asymptotically stable, and delays \( \tau_1, \tau_2, \) and \( \tau_3 \) do not impact the stability of \( E_1 \).

Calculating the derivative of \( V_3(t) \) along solutions of model (2), we obtain

\[
\frac{dV_3(t)}{dt} = s(x) \left( 1 - \frac{f(x_2, v_2)}{f(x, v_2)} \right)
\]

\[
+ f(x, v) \frac{f(x_2, v_2)}{f(x, v_2)} - f(x_2, v_2) \frac{g_2(v)}{g_2(v_2)}
\]

\[
+ M_1 + M_2,
\]

where

\[
M_1 = p \frac{m_1 \tau_1}{c} g_1(y_2) g_4(z) - \frac{b e^{m_1 \tau_1}}{c} g_4(z)
\]

\[
= p \frac{m_1 \tau_1}{c} g_4(z) (g_1(y_2) - g_1(\overline{y}_4)),
\]

\[
M_2 = f(x_2, v_2) \ln g_2(v) \frac{f(x_2, v_2)}{g_2(v_2)} - f(x_2, v_2)
\]

\[
\cdot H \left( \frac{g_2(v_2)}{g_1(y_2)} \frac{g_1(y_2) f(x_2, v_2)}{g_2(v) f(x_2, v_2)} \right) - f(x_2, v_2)
\]

\[
\cdot H \left( \frac{g_1(y_2) f(x_2, v_2)}{g_2(v)} \right) - f(x_2, v_2)
\]

Therefore,

\[
\frac{dV_3(t)}{dt} = (s(x) - s(x_2)) \left( 1 - \frac{f(x_2, v_2)}{f(x, v_2)} \right)
\]

\[
- f(x_2, v_2) H \left( \frac{g_2(v_2) g_1(y_2) f(x_2, v_2)}{g_2(v_2)} \right)
\]

\[
+ f(x_2, v_2) \frac{g_2(v)}{g_2(v_2)} \left( \frac{f(x, v)}{f(x, v_2)} - 1 \right)
\]
\[
\left( \frac{g_2(v_2)}{g_2(v)} - \frac{f(x,v_2)}{f(x,v)} \right) + pe^{m_1}g_4(x)
\]
\[
\left( g_1(y_2) - g_1(\overline{y}_2) \right) - f(x_2,v_2)
\]
\[
\left( \frac{g_2(v)f(x,v_2)}{g_2(v)} - \frac{f(x_2,v_2)}{f(x,v)} \right) - f(x_2,v_2)
\]
\[
\left( \frac{g_1(y_2)f(x(t-t_1),v(t-t_1))}{g_1(y)f(x_2,v_2)} \right) - f(x_2,v_2)H\left( \frac{f(x_2,v_2)}{f(x,v)} \right).
\]

(37)

Note that \((s(x) - s(x_2))(1 - f(x_2,v_2)/f(x,v_2)) \leq 0\), and
\[
\left( \frac{f(x,v)}{f(x_2,v_2)} - 1 \right) \left( \frac{g_2(v_2)}{g_2(v)} - \frac{f(x_2,v_2)}{f(x,v)} \right) \leq 0
\]
for \(t \geq 0\).

Since \(y_2 \leq \overline{y}_2\), we have \(dV_2(t)/dt \leq 0\), and \(dV_3(t)/dt = 0\) if and only if \(x(t) = x_2\), \(y(t) = y_2\), \(v(t) = v_2\), and \(z(t) = 0\).

From LaSalle's invariance principle [36], we finally have that \(E_2\) is globally asymptotically stable when \(R_1 > 1\) and \(R_2 \leq 1\).

Next, consider conclusion (b). By computing, the characteristic equation of linearization system of model (2) at \(E_2\) is
\[
f_1(\lambda) f_2(\lambda) = 0,
\]
where \(f_1(\lambda) = \lambda + b - ce^{-\lambda \tau} g_1(y_2)\) and
\[
f_2(\lambda) = \begin{bmatrix}
    a_{11} & 0 & a_{13} & 0 \\
    a_{21} & a_{22} & a_{23} & 0 \\
    0 & a_{32} & a_{33} & a_{34} \\
    0 & 0 & a_{43} & a_{44}
\end{bmatrix},
\]
where
\[
a_{11} = \lambda - s'(x_2) + \frac{\partial f(x_2,v_2)}{\partial x},
\]
\[
a_{13} = \frac{\partial f(x_2,v_2)}{\partial v},
\]
\[
a_{21} = -e^{-(m_1 + \lambda)\tau} \frac{\partial f(x_2,v_2)}{\partial x},
\]
\[
a_{22} = \lambda + ag_1'(y_2),
\]
\[
a_{23} = -e^{-(m_1 + \lambda)\tau} \frac{\partial f(x_2,v_2)}{\partial v},
\]
\[
a_{32} = -ke^{-(m_1 + \lambda)\tau} g_1'(y_2),
\]
\[
a_{33} = \lambda + (u + ag_3'(w_2)) g_2'(v_2),
\]
\[
a_{34} = q g_2(v_2) g_3'(w_2),
\]
\[
a_{43} = -rg_2'(v_2) g_3'(w_2),
\]
\[
a_{44} = \lambda + (h - rg_2'(v_2)) g_3'(w_2).
\]

(41)

When \(R_1 > 1\), we have \(f_1(0) = 0 - cg_1(y_2) = ct g_1(\overline{y}_2) - g_1(y_2) < 0\) and \(\lim_{t \to +\infty} f_1(\lambda) = +\infty\). Hence, there is also a positive root \(\lambda^*\) such that \(f_1(\lambda^*) = 0\). Therefore, when \(R_3 > 1\), \(E_3\) is unstable. This completes the proof.

Remark 11. Theorem 10 shows that if only equilibrium \(E_0, E_1, \) and \(E_2\) exist, then when \(R_3 \leq 1\) and \(R_1 > 1\), \(E_3\) is globally asymptotically stable, and delays \(\tau_1, \tau_2, \) and \(\tau_3\) do not impact the stability of \(E_2\).

3.4. Stability of Equilibrium \(E_3\). On the stability analysis of equilibrium \(E_3\), we only discuss the following case: \(\tau_1 \geq 0\), \(\tau_2 \geq 0\), and \(\tau_3 = 0\). Other cases, \(\tau_1 \geq 0\), \(\tau_2 \geq 0\), and \(\tau_3 \geq 0\), are numerically verified for bifurcation phenomena and stability switches of \(E_3\), but the analytic analysis is left as an open problem. Before the proof of the theorem, we have the following Lemma.

Lemma 12. Suppose \(R_3 > 1\) and \(R_4 \leq 1\). Let \(\overline{E}_4 = (\overline{x}_4, \overline{y}_4, \overline{v}_4, \overline{w}_4)\) be the solution of (4) with \(\overline{y}_4 = g_2^{-1}(h/\rho)\) and \(\overline{v}_4 = g_1^{-1}(b/\nu)\). Then for equilibrium \(E_3 = (x_3, y_3, v_3, z_3, 0)\), \(v_3 \leq \overline{v}_4\).

Proof. Since \(\overline{E}_4\) satisfies (4), we have \(\overline{y}_4 = g_2^{-1}(b/\rho)\), \(\overline{v}_4 = g_1^{-1}(b/\nu)\), and \(\overline{v}_4 = x_2\). Compared with \(E_3\), we get \(\overline{y}_4 = y_4\) and \(\overline{v}_4 = v_4\). When \(R_4 \leq 1\), we obtain \(\overline{w}_4 < 0\). Since
\[
ke^{-m_3 \tau_3} g_1(y_3) = ug_2'(v_3),
\]
\[
ke^{-m_3 \tau_3} g_1(\overline{y}_4) = ug_2'(\overline{v}_4) + g_2(\overline{v}_4) g_3'(\overline{w}_4),
\]

it follows that \(v_3 \leq \overline{v}_4\) if \(R_2 > 1\) and \(R_4 \leq 1\). This completes the proof.

Theorem 13. Let \(R_2 > 1\). (a) If \(R_4 \leq 1\) and \(\tau_3 = 0\), then infection equilibrium \(E_3\) with only CTL response is globally asymptotically stable.

(b) If \(R_4 > 1\), then \(E_3\) is unstable.

Proof. We first consider conclusion (a). Define a Lyapunov functional \(V_4(t)\) as follows:
\[
V_4(t) = x(t) - \int_{x_3}^{x(t)} \frac{f(x_3,v_3)}{f(\theta,v_3)} d\theta
\]
\[
+ e^{m_3 \tau_3} \left( y(t) - \int_{y_3}^{y(t)} \frac{g_1(y_3)}{g_1(\theta)} d\theta \right)
\]
\[
+ \frac{f(x_3,v_3)}{g_2'(v_3)} u \left( v(t) - \int_{v_3}^{v(t)} \frac{g_2(v_3)}{g_2(\theta)} d\theta \right)
\]
\[
+ \frac{pe^{m_1 \tau_1}}{c} \left( z(t) - \int_{z_3}^{z(t)} \frac{g_3(z_3)}{g_3(\theta)} d\theta \right).
\]
\[ \frac{dV_4(t)}{dt} = s(x) \left( 1 - \frac{f(x, v)}{f(x, v_3)} \right) + f(x, v) \frac{f(x, v_3)}{f(x, v)} \]

Calculating the derivative of \( V_4(t) \) along solutions of model (2), we obtain that

\[
\frac{dV_4(t)}{dt} = s(x) \left( 1 - \frac{f(x, v)}{f(x, v_3)} \right) + f(x, v) \frac{f(x, v_3)}{f(x, v)}
\]

for \( t \geq 0 \).

Note that \( s(x) - s(x_3) (1 - f(x, v)/f(x, v_3)) \leq 0 \), and

\[
\left( \frac{f(x, v)}{f(x, v_3)} - 1 \right) \left( \frac{g_2(v)}{g_2(v_3)} - \frac{g_3(w)}{g_2(v_3)} \right) \leq 0
\]

for \( t \geq 0 \).

Since \( v_3 \leq v_3 \), we have \( dV_4(t) / dt \leq 0 \), and \( dV_4(t) / dt = 0 \) if and only if \( x(t) = x_3, y(t) = y_3, v(t) = v_3 \), and \( w(t) = 0 \). From LaSalle’s invariance principle [36], we finally have that \( E_3 \) is globally asymptotically stable when \( r_3 = 0, R_0 > 1, R_2 > 1, \) and \( R_1 \leq 1 \).

Next, we consider conclusion (b). By computing, the characteristic equation of the linearization system of model (2) at \( E_3 \) is

\[
(\lambda + h - rg_2(v_3)) f(\lambda) = 0,
\]

where

\[
\begin{bmatrix}
a_{11} & a_{13} & 0 \\
a_{21} & a_{22} & a_{23} & a_{24} \\
0 & a_{32} & a_{33} & 0 \\
0 & a_{42} & 0 & a_{44}
\end{bmatrix}
\]

and

\[
a_{21} = (\acute{\lambda} + u g_1(y)) g'_1(y),
\]

\[
a_{22} = \lambda + p g_1(y) g'_1(y),
\]

\[
a_{23} = -e^{-(m_1+\lambda) \tau_1},
\]

\[
a_{24} = a_2 y g_1(y) g'_1(y),
\]

\[
a_{32} = -ke^{-(m_2+\lambda) \tau_2} g'_1(y),
\]

\[
a_{33} = a_3 y g_1(y) g'_1(y),
\]

\[
a_{42} = -c e^{-(m_3+\lambda) \tau_3} g'_1(y),
\]

\[
a_{44} = \lambda + b g_1(y) e^{-\lambda \tau_4} g'_4(z).
\]

When \( R_4 > 1 \), we have \( h - rg_2(v_3) = r(g_2(v_3) - g_2(v_3))) < 0 \). Hence, there is a positive root \( \lambda^* = rg_2(v_3) - h \). Therefore, when \( R_4 > 1, E_3 \) is unstable for any \( \tau_1 \geq 0, \tau_2 \geq 0, \) and \( \tau_3 \geq 0 \). This completes the proof.

Remark 14. Theorem 13 shows that if only equilibria \( E_0, E_1, \) and \( E_2 \) exist, then when \( R_2 > 1, R_1 \leq 1, \) and \( r_3 = 0 \), \( E_3 \) is globally asymptotically stable, and delays \( \tau_1 \) and \( \tau_2 \) do not impact the stability of \( E_3 \).

3.5. Stability of Equilibrium \( E_4 \). On the stability analysis of equilibrium \( E_4 \), we here only discuss the following case: \( \tau_1 = 0, \tau_2 = 0, \) and \( \tau_3 = 0 \). However, for the cases \( \tau_1 \geq 0, \tau_2 \geq 0, \) and \( \tau_3 \geq 0, \) the theoretical analysis is very complicated. We will give numerical analysis for this case in the next section.

Theorem 15. If \( r_3 = 0, R_1 > 1, \) and \( R_4 > 1, \) then infection equilibrium \( E_4 \) with both antibody and CTL immune responses is globally asymptotically stable.
Proof. Define a Lyapunov functional $V_5(t)$ as follows:

$$V_5(t) = x(t) - \int_{x_i}^{x(t)} \frac{f(x, v_k)}{f(x, v_k)} \frac{d\theta}{\bar{\theta}} + e^{m \tau_i} \left( y(t) - \int_{y_i}^{y(t)} \frac{g_1(\bar{\theta}, v_k)}{g_1(\bar{\theta})} d\bar{\theta} \right)$$

$$+ \frac{f(x, v_k)}{g_2(v_k)} \left( v(t) - \int_{v_i}^{v(t)} \frac{g_1(\bar{\theta}, v_k)}{g_1(\bar{\theta})} d\bar{\theta} \right) + f(x_i, v_k)$$

$$- \int_{z_i}^{z(t)} \frac{g_1(z)}{g_1(\bar{\theta})} d\bar{\theta} \right) + f(x_i, v_k)$$

$$+ \int_{-\tau}^{0} \left( f(x(t+s), v(t+s)) - f(x_i, v_k) \right) ds.$$

Using the above similar method, we obtain

$$\frac{dV_5(t)}{dt} = f(x, v_k) \left( H \left( \frac{f(x, v_k)}{f(x, v_k)} \right) - \frac{f(x, v_k)}{f(x, v_k)} \right)$$

$$+ \int_{-\tau}^{0} \left( f(x(t+s), v(t+s)) - f(x_i, v_k) \right) ds.$$

Note that $(s(x) - s(x_i))(1 - f(x_i, v_k)/f(x, v_k)) \leq 0$, and

$$\left( \frac{f(x, v)}{f(x, v)} - 1 \right) \left( g_2(v_k) - \frac{f(x, v_k)}{f(x, v_i)} \right) \leq 0$$

for $t \geq 0$. Obviously, we have $dV_5(t)/dt \leq 0$, and $dV_5(t)/dt = 0$ if and only if $x(t) = x_i$, $y(t) = y_i$, and $v(t) = v_i$. From LaSalle's invariance principle [36], we finally have that $E_4$ is globally asymptotically stable when $\tau_3 = 0$, $R_3 > 1$, and $R_4 > 1$. This completes the proof.

Remark 16. Theorem 15 shows that if equilibria $E_0$, $E_1$, $E_2$, $E_3$, and $E_4$ exist, then when $R_3 > 1$, $R_4 > 1$, and $\tau_3 = 0$, $E_4$ is globally asymptotically stable, and delays $\tau_1$ and $\tau_2$ do not impact the stability of $E_4$.

4. Numerical Simulations

In the above section, we obtain the global asymptotic stability of equilibria $E_3$ and $E_4$ when the delay $\tau_3 = 0$. In this section, by using the numerical simulation, it is shown that the Hopf bifurcation and stability switches occur at equilibria $E_3$ and $E_4$ in the case $\tau_3 > 0$.

Example 17. Corresponding to model (2), we consider the following model:

$$\frac{dx(t)}{dt} = \lambda - dx(t) + r_1 x(t) \left( 1 - \frac{x(t)}{K} \right) - \beta x(t) \left( \left( v(t) - b_1 \right) e^{-c(v(t))} + b_1 \right),$$

$$\frac{dy(t)}{dt} = \beta e^{-m \tau_i} x(t) \left( t - \tau_1 \right) - ay(t) - py(t) z(t),$$

$$\frac{dz(t)}{dt} = cy(t) z(t) - bz(t),$$

$$\frac{dw(t)}{dt} = r v(t) w(t) - hw(t),$$

where $b_1, c_1 > 0$ are constants. We have $s(x) = \lambda - dx(x) + r_1 (x(1 - x/K))$, $f(x, v) = \beta x(v) v(1 - b_1 e^{-c(v(b_1) + b_1)})$, and $g_1(\xi) = \xi (i = 1, 2, 3, 4)$. It can easily verify that $(H_1)(-H_4)$ hold. Taking $\lambda = 0.01, d = 0.01, r_1 = 0.6, K = 500, \beta = 0.3, c_1 = 0.01, b_1 = 0.01, \alpha = 0.5, p = 1, k = 0.4, q = 1.1, b = 0.15, m_1 = m_2 = 0.01, g = 1.5, h = 1, \tau_1 = 2$, and $\tau_2 = 5$, choose $\tau_3$ as free parameter. By computing, $R_3 = 34.4139 > 1$, $R_4 = 0.2854 < 1$, and $E_3 = (462.1965, 1.5000, 0.1902, 15.3959, 0)$. From Figures 1–8, we see that as $\tau_3$ increases the complex dynamical behaviors of equilibrium $E_3$ occur.
Figure 1: Taking $\tau_3 = 0.2$, we have $R_2 = 34.4139 > 1$ and $R_4 = 0.2854 < 1$, and the infection equilibrium $E_3$ with only CTL response is asymptotically stable.
Figure 2: Taking $r_3 = 2$, we have $R_2 = 34.4139 > 1$ and the Hopf bifurcation at infection equilibrium $E_3$ with only CTL response occurs.
Figure 3: Taking $\tau_3 = 4$, we have $R_2 = 34.4139 > 1$ and $R_4 = 0.2854 < 1$, and the infection equilibrium $E_3$ with only CTL response is asymptotically stable.
Figure 4: Taking $\tau_3 = 15$, we have $R_2 = 34.4139 > 1$ and the Hopf bifurcation at infection equilibrium $E_3$ with only CTL response occurs.
Figure 5: Taking $\tau_j = 0.1$, we have $R_3 = 1.8912 > 1$ and $R_4 = 2.7693 > 1$, and the infection equilibrium $E_4$ with both CTL and antibody responses is asymptotically stable.
Figure 6: Taking $\tau_3 = 2.5$, we have $R_3 = 1.8912 > 1$ and $R_4 = 2.7693 > 1$, and the Hopf bifurcation at infection equilibrium $E_4$ with both CTL and antibody responses occurs.
Figure 7: Taking $\tau_3 = 6$, we have $R_3 = 1.8912 > 1$ and $R_4 = 2.7693 > 1$, and the infection equilibrium $E_4$ with both CTL and antibody responses is asymptotically stable.
Figure 8: Taking $r_3 = 16$, we have $R_3 = 1.8912 > 1$ and the Hopf bifurcation at infection equilibrium $E_4$ with both CTL and antibody responses occurs.
Example 18. Corresponding to model (2), we consider the following model:

\[
\begin{align*}
\frac{dx(t)}{dt} &= \lambda - dx(t) - \frac{βx(t)v(t)}{1 + a_1x(t) + b_1v(t) + a_2b_2x(t)v(t)} , \\
\frac{dy(t)}{dt} &= \frac{βe^{-m_1v_1}x(t - τ_1)v(t - τ_1)}{1 + a_1x(t - τ_1) + b_1v(t - τ_1) + a_2b_2x(t - τ_1)v(t - τ_1)} - ay(t) - py(t)z(t) , \\
\frac{dz(t)}{dt} &= cy(t - τ_1)z(t - τ_1) - βz(t) , \\
\frac{dw(t)}{dt} &= r v(t) w(t) - hw(t) ,
\end{align*}
\]

where \(a_1, b_1 > 0\) are constants. We have \(s(x) = \lambda - dx(t), f(x, v) = \frac{βx(v)v(t)}{1 + a_1x(t) + b_1v(t) + a_2b_2x(t)v(t)},\) and \(g_i(\xi) = ξ (i = 1, 2, 3, 4).\) It is easily verified that \((H_1)-(H_4)\) hold.

Taking \(λ = 10, d = 0.01, β = 0.25, a_1 = 0.01, b_1 = 0.01, a = 0.5, p = 1, k = 0.4, u = 3, q_1 = 1, c = 0.1, b = 0.15, m_1 = m_2 = 0.01, r = 1.5, h = 0.1, τ_1 = 5,\) and \(τ_2 = 8,\) choose \(τ_1\) as free parameter. By computing, \(R_3 = 1.8912 > 1,\) \(R_4 = 5.3039 > 1,\) and \(E_4 = (850.8857, 1.5000, 0.6667, 0.4456)\). From Figures 5–8, we see that as \(τ_1\) increases the complex dynamical behaviors of equilibrium \(E_4\) occur.

5. Discussion

In this paper we have considered an in-host model with intracellular delay \(τ_1,\) virus replication delay \(τ_2,\) and immune response delay \(τ_3,\) given by (2) together with assumptions \((H_1)-(H_4),\) which describes the dynamics among uninfected cells, infected cells, virus, CTL responses, and antibody responses. The model allows for general target-cell dynamics \(s(x),\) including a nonlinear incidence \(f(x, v),\) discrete delays, and state-dependent removal functions \(g_i (i = 1, 2, 3, 4).\) This general model includes many existing models in the literature as special cases. Dynamical analysis of model (2) shows that \(τ_1, τ_2,\) and \(τ_3\) play different roles in the stability of the equilibria. Particularly, we see that \(τ_3\) may impact the stability of equilibria \(E_3\) and \(E_4.\)

By the analysis, we have shown that when \(R_0 \leq 1, E_4\) is globally asymptotically stable, which means that the virus is cleared. When \(R_0 > 1, R_1 \leq 1,\) and \(R_2 \leq 1, E_1\) is globally asymptotically stable, which means that the infection is successful, but the establishments of both antibody and CTLs immune responses are unsuccessful. When \(R_1 > 1\) and \(R_3 \leq 1, E_2\) is globally asymptotically stable, which implies that the antibody response is established, but the infected cells are too weak to stimulate CTL immune response. With respect to the analysis of \(E_3,\) we consider special cases \(τ_3 = 0, τ_1 \geq 0,\) and \(τ_2 \geq 0;\) when \(R_3 > 1\) and \(R_4 \leq 1, E_3\) is globally asymptotically stable, which means that the CTL immune response is determined, but the viral loads are so small that it cannot activate the antibody response. About the stability of \(E_4,\) we have obtained that for special case, \(τ_1 = 0, τ_2 \geq 0,\) and \(τ_3 \geq 0,\) when \(R_3 > 1\) and \(R_4 \geq 1, E_4\) is globally asymptotically stable, that is, susceptible cells, infected cells, free virus, CTLs, and antibodies coexist in vivo.

Based on Theorems 13 and 15, we obtain that the intracellular delay \(τ_1\) and virus replication delay \(τ_2\) for model (2) do not cause Hopf bifurcation. Moreover, \(R_0\) plays a crucial role in virus infection dynamics. Actually, in model (2), \(R_0\) is a decreasing function on time delay \(τ_1.\) When all other parameters are fixed and delay \(τ_1\) is sufficiently large, \(R_0\) becomes less than one, only infection-free equilibrium \(E_0\) exists, and the virus is cleared in the host. By biological meanings, intracellular delay plays a positive role in virus infection process in order to eliminate virus. Sufficiently large intracellular delay makes the virus development slower and the virus has been controlled and disappeared. This gives us some suggestions on new drugs to prolong the time of infected cells producing virus. However, by the recent research of Li and Shu [37], in the case of the coexistence of viral infection model, the intracellular delay produces Hopf bifurcation only when the mitosis rate is sufficiently large.

When \(τ_1 > 0,\) by numerical simulations, it is shown that the Hopf bifurcation and stability switches occur at equilibria \(E_3\) and \(E_4\) as \(τ_3\) increases. Figures 1–4 indicate that \(E_3\) remains stable as \(τ_3 > 0\) is small, and along with the increase of \(τ_3,\) equilibrium \(E_3\) becomes unstable and periodic oscillations appear. It shows that stability switches occur as delay \(τ_3\) increases. Similarly, from Figures 5–8, we see that along with the increases of \(τ_3 > 0\) the dynamical behaviors of model (53) at equilibrium \(E_4\) appear as very large diversification. Particularly, when \(τ_3\) is small enough, \(E_4\) is asymptotically stable and when \(τ_3\) is increasing, the stability switches occur at equilibrium \(E_4,\) and when \(E_4\) is unstable, a Hopf bifurcation occurs. Finally, when \(τ_3\) is enough large, equilibrium \(E_4\) always is unstable. Summarizing these discussions, we have the conclusion that \(τ_3\) affects markedly the stability of equilibria \(E_3\) and \(E_4.\) From the numerical simulations, we observe that immune response delay \(τ_3\) can cause Hopf bifurcation. Upon primary infection, the sustained oscillations from the Hopf bifurcation imply that the pathogen may not always be cleared entirely with the CTL responses which usually occur in a few days after serum conversion. As the increase of immune delay \(τ_3,\) we know that the drug prevents virus from continuing through their cell cycle, thus trapping them at some point during interphase, where the cells die from natural causes. Then susceptible cells, infected cells, free virus, CTLs, and antibodies reach a stable level in the host. When immune delay \(τ_3\) continuously increases, the activation of the immune cell is to fight against the malignant virus cells. Thus susceptible cells, infected cells, free virus, CTLs, and antibodies exhibit sustained periodic oscillations in the chronic phase of infection. This explains the fact that the immune response delay plays negative roles in controlling disease progression.
Observing all obtained results in this paper, we can directly put forward the following open questions which need to be further studied in the future.

For one, in addition to $\tau_1$, $\tau_2$, and $\tau_3$, antibody response delay $\tau_4$ is also considered, whether the results obtained in this paper can be extended to a virus infection model with nonlinear incidence rate and four time delays. For another, we obtain the Hopf bifurcation and stability switches at equilibria $E_3$ and $E_4$ for model (2) only by using the numerical simulation method for special examples (52) and (53). Up to now, the theoretical analysis and results in this aspect are few and rough. Therefore, a systemic and complete theoretical analysis and results will be a very estimable and significative subject.

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was partially supported by the National Natural Science Foundation of China (Grant nos. 11271312, 11261056, and 11661076), the Doctoral Subjects Foundation of The Ministry of Education of China (Grant no. 20136511L0001), and the Natural Science Foundation of Xinjiang University (starting research fund for the Xinjiang University doctoral graduates, Grant no. BS150202).

References

[1] Y. Yan and W. Wang, "Global stability of a five-dimensional model with immune responses and delay," Discrete and Continuous Dynamical Systems Series B, vol. 17, no. 1, pp. 401–416, 2012.

[2] P. Balasubramaniam, P. Tamilalagan, and M. Prakash, "Bifurcation analysis of HIV infection model with antibody and cytotoxic T-lymphocyte immune responses and Beddington-DeAngelis functional response," Mathematical Methods in the Applied Sciences, vol. 38, no. 7, pp. 1330–1341, 2015.

[3] A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho, "HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time," Science, vol. 271, no. 5255, pp. 1582–1586, 1996.

[4] M. A. Nowak, S. Bonhoeffer, A. M. Hill, R. Boehme, H. C. Thomas, and H. Mcdade, "Viral dynamics in hepatitis B virus infection," Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 9, pp. 4398–4402, 1996.

[5] P. W. Nelson and A. S. Perelson, "Mathematical analysis of delay differential equation models of HIV-1 infection," Mathematical Biosciences, vol. 179, no. 1, pp. 73–94, 2002.

[6] A. Korobeinikov, "Global properties of basic virus dynamics models," Bulletin of Mathematical Biology, vol. 66, no. 4, pp. 879–883, 2004.

[7] M. Y. Li and H. Shu, "Global dynamics of an in-host viral model with intracellular delay," Bulletin of Mathematical Biology, vol. 72, no. 6, pp. 1492–1505, 2010.

[8] R. V. Culshaw and S. Ruan, "A delay-differential equation model of HIV infection of CD4+ T-cells," Mathematical Biosciences, vol. 165, no. 1, pp. 27–39, 2000.

[9] Y. Wang, Y. Zhou, J. Wu, and J. Heffernan, "Oscillatory viral dynamics in a delayed HIV pathogenesis model," Mathematical Biosciences, vol. 219, no. 2, pp. 104–112, 2009.

[10] P. De Leenheer and H. L. Smith, "Virus dynamics: a global analysis," SIAM Journal on Applied Mathematics, vol. 63, no. 4, pp. 1313–1327, 2003.

[11] L. Wang and M. Y. Li, "Mathematical analysis of the global dynamics of a model for HIV infection of CD4+ T cells," Mathematical Biosciences, vol. 200, no. 1, pp. 44–57, 2006.

[12] X. Zhou and J. Cui, "Global stability of the viral dynamics with Crowley–Martin functional response," Bulletin of the Korean Mathematical Society, vol. 48, no. 3, pp. 555–574, 2011.

[13] A. S. Perelson and P. W. Nelson, "Mathematical analysis of HIV-1 dynamics in vivo," SIAM Review, vol. 41, no. 1, pp. 3–44, 1999.

[14] H. Shu, L. Wang, and J. Watmough, "Global stability of a nonlinear viral infection model with infinitely distributed intracellular delays and CTL immune responses," SIAM Journal on Applied Mathematics, vol. 73, no. 3, pp. 1280–1302, 2013.

[15] D. Li and W. Ma, "Asymptotic properties of a HIV-1 infection model with time delay," Journal of Mathematical Analysis and Applications, vol. 335, no. 1, pp. 683–691, 2007.

[16] X. Song and A. U. Neumann, "Global stability and periodic solution of the viral dynamics," Journal of Mathematical Analysis and Applications, vol. 329, no. 1, pp. 281–297, 2007.

[17] R. A. Arnaout, M. N. Owak, and D. Wodarz, "HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing?", Proceedings of the Royal Society B: Biological Sciences, vol. 265, no. 1450, pp. 1347–1354, 2000.

[18] K. Wang, W. Wang, and X. Liu, "Global stability in a viral infection model with lytic and nonlytic immune responses," Computers & Mathematics with Applications, vol. 51, no. 9-10, pp. 1593–1610, 2006.

[19] M. A. Nowak and C. R. M. Bangham, "Population dynamics of immune responses to persistent viruses," Science, vol. 272, no. 5258, pp. 74–79, 1996.

[20] J. Wang, J. Pang, T. Kuniya, and Y. Enatsu, "Global threshold dynamics in a five-dimensional virus model with cell-mediated, humoral immune responses and distributed delays," Applied Mathematics and Computation, vol. 241, pp. 298–316, 2014.

[21] K. Hatta, M. Kabouze, and N. Youssi, "Dynamics of a generalized viral infection model with adaptive immune response," International Journal of Dynamics and Control, vol. 3, no. 3, pp. 253–261, 2015.

[22] Y. Wang, Y. Zhou, F. Brauer, and J. M. Heffernan, "Viral dynamics model with CTL immune response incorporating antiretroviral therapy," Journal of Mathematical Biology, vol. 67, no. 4, pp. 901–934, 2013.

[23] K. A. Pawelek, S. Liu, F. Palevani, and L. Rong, "A model of HIV-1 infection with two time delays: mathematical analysis and comparison with patient data," Mathematical Biosciences, vol. 235, no. 1, pp. 98–109, 2012.

[24] Z. Yuan and X. Zou, "Global threshold dynamics in an HIV virus model with nonlinear infection rate and distributed invasion and production delays," Mathematical Biosciences and Engineering, vol. 10, no. 2, pp. 483–498, 2013.

[25] A. M. Elaiw and N. H. AlShamrani, "Global stability of humoral immunity virus dynamics models with nonlinear infection rate and removal," Nonlinear Analysis: Real World Applications, vol. 26, pp. 161–190, 2015.

[26] Z. Wang and R. Xu, "Stability and Hopf bifurcation in a viral infection model with nonlinear incidence rate and delayed
immune response,” Communications in Nonlinear Science and Numerical Simulation, vol. 17, no. 2, pp. 964–978, 2012.

[27] X. Wang, A. Elaiw, and X. Song, “Global properties of a delayed HIV infection model with CTL immune response,” Applied Mathematics and Computation, vol. 218, no. 18, pp. 9405–9414, 2012.

[28] H. Zhu, Y. Luo, and M. Chen, “Stability and Hopf bifurcation of a HIV infection model with CTL-response delay,” Computers & Mathematics with Applications. An International Journal, vol. 62, no. 8, pp. 3091–3102, 2011.

[29] Z. Hu, J. Zhang, H. Wang, W. Ma, and F. Liao, “Dynamics analysis of a delayed viral infection model with logistic growth and immune impairment,” Applied Mathematical Modelling, vol. 38, no. 2, pp. 524–534, 2014.

[30] X. Tian and R. Xu, “Global stability and Hopf bifurcation of an HIV-1 infection model with saturation incidence and delayed CTL immune response,” Applied Mathematics and Computation, vol. 237, pp. 146–154, 2014.

[31] T. Wang, Z. Hu, and F. Liao, “Stability and Hopf bifurcation for a virus infection model with delayed humoral immunity response,” Journal of Mathematical Analysis and Applications, vol. 411, no. 1, pp. 63–74, 2014.

[32] S. Wang and D. Zou, “Global stability of in-host viral models with humoral immunity and intracellular delays,” Applied Mathematical Modelling, vol. 36, no. 3, pp. 1313–1322, 2012.

[33] Y. Ji, “Global stability of a multiple delayed viral infection model with general incidence rate and an application to HIV infection,” Mathematical Biosciences and Engineering, vol. 12, no. 3, pp. 525–536, 2015.

[34] H. Zhu and X. Zou, “Dynamics of a HIV-1 Infection model with cell-mediated immune response and intracellular delay,” Discrete and Continuous Dynamical Systems. Series B, vol. 12, no. 2, pp. 511–524, 2009.

[35] P. H. Crowley and E. K. Martin, “Functional responses and interference within and between year classes of a dragonfly population,” Journal of the North American Benthological Society, vol. 8, no. 3, pp. 211–221, 1989.

[36] Y. Kuang, Delay Differential Equations with Applications in Population Dynamics, Academic Press, San Diego, Calif, USA, 1993.

[37] M. Y. Li and H. Shu, “Joint effects of mitosis and intracellular delay on viral dynamics: two-parameter bifurcation analysis,” Journal of Mathematical Biology, vol. 64, no. 6, pp. 1005–1020, 2012.